Neuroblastoma Global Market Report 2025

Description

Neuroblastoma is a type of cancer that predominantly affects children, originating from immature nerve cells called neuroblasts. This cancer often develops in the adrenal glands, which sit atop the kidneys, but it can also occur in other regions of the abdomen, chest, neck, or pelvis. Symptoms associated with neuroblastoma may include abdominal pain, swelling, fatigue, and in some cases, bone pain or the presence of lumps.

The primary product types for treating neuroblastoma include tablets, vaccines, and others. Tablets are solid oral dosages containing active ingredients, binders, and fillers, used in the treatment of neuroblastoma to administer chemotherapy or targeted therapy drugs. Treatment options for neuroblastoma include chemotherapy, immunotherapy, and other approaches, which are distributed through various channels, both online and offline. These treatments are typically used in hospitals and clinics.

The neuroblastoma market research report is one of a series of new reports from The Business Research Company that provides neuroblastoma market statistics including the neuroblastoma industry global market size regional shares competitors with the neuroblastoma market share detailed neuroblastoma market segments market trends and opportunities and any further data you may need to thrive in the neuroblastoma industry. This neuroblastoma market research report delivers a complete perspective of everything you need with an in-depth analysis of the current and future scenarios of the industry.

The neuroblastoma market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth observed during the historic period can be attributed to factors such as the rising prevalence of neuroblastoma, increased research and development focused on pediatric neuroblastoma treatments, a higher incidence of childhood cancer, and growing government funding and support.

The neuroblastoma market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth projected for the forecast period can be attributed to factors such as rising government funding, a higher incidence of the disease, an increasing emphasis on early detection, a growing prevalence of genetic mutations, and advancements in research and understanding. Key trends expected during this period include the development of drugs targeting specific molecular pathways, innovations in non-invasive imaging technologies, progress in gene-editing technologies, a greater focus on personalized treatment approaches, and the development of radiolabeled compounds.

The growth of the neuroblastoma market is expected to be driven by the rising incidence of childhood cancer. Childhood cancer refers to a group of cancers that primarily affect children and adolescents, often targeting organs such as the brain, blood, and bones, and requiring specialized treatment methods. This increase in childhood cancer cases can be attributed to several factors, including advancements in diagnostic techniques, greater awareness, environmental exposures, genetic factors, and progress in medical research. Neuroblastoma treatments offer targeted therapies for childhood cancer, allowing for early intervention that reduces the risk of recurrence and improves the prognosis for young patients. For example, in May 2024, the American Cancer Society, a US-based professional organization, projected that around 9,620 children under the age of 15 in the United States would be diagnosed with cancer in 2024, up from 5,290 cases in 2023. As a result, the rising incidence of childhood cancer is a key factor driving the growth of the neuroblastoma market.

Leading companies in the neuroblastoma market are concentrating on developing innovative therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to more effectively and safely target cancer cells. These antibodies are engineered to specifically target the GD2 molecule on cancer cells while minimizing immune rejection by incorporating human components. For example, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced that it had in-licensed Hu14.18K322A (Hu14.18) from St. Jude Children's Research Hospital. This antibody is designed for the treatment of newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. According to the agreement, Renaissance has obtained exclusive rights to develop, manufacture, and commercialize Hu14.18 in key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.

In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, completed the acquisition of Apeiron Biologics AG for $100 million. Through this acquisition, Ligand gains royalty rights to Qarziba and aims to enhance its commercial royalty portfolio by adding a high-value immunotherapy for high-risk neuroblastoma. This move is expected to drive growth by generating long-term, predictable revenue from a diverse range of key products. Apeiron Biologics AG, based in Austria, is a biotech company specializing in the development of immunotherapies for neuroblastoma.

Major players in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroblastoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Neuroblastoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuroblastoma market consists of revenues earned by entities by providing services such as diagnosis and imaging, oncology treatment, and stem cell transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroblastoma market also consists of sales of radiopharmaceuticals, monoclonal antibodies, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuroblastoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuroblastoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuroblastoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuroblastoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product Types: Tablets; Vaccines; Other Product Types
2) By Treatment Type: Chemotherapy; Immunotherapy; Other Treatment Types
3) By Distribution Channel: Online; Offline
4) By End-User: Hospitals; Clinics
Subsegments:
1) By Tablets: Oral Chemotherapy Tablets; Targeted Therapy Tablets
2) By Vaccines: Immunotherapy Vaccines; Therapeutic Vaccines
3) By Other Product Types: Injectable Drugs; Monoclonal Antibodies; Cell Therapy Products
Companies Mentioned:Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Sartorius AG; Recordati S.p.A
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33831

1. Executive Summary

2. Neuroblastoma Market Characteristics

3. Neuroblastoma Market Trends And Strategies

4. Neuroblastoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neuroblastoma Growth Analysis And Strategic Analysis Framework

5.1. Global Neuroblastoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neuroblastoma Market Growth Rate Analysis
5.4. Global Neuroblastoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neuroblastoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neuroblastoma Total Addressable Market (TAM)

6. Neuroblastoma Market Segmentation

6.1. Global Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablets
Vaccines
Other Product Types
6.2. Global Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunotherapy
Other Treatment Types
6.3. Global Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online
Offline
6.4. Global Neuroblastoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
6.5. Global Neuroblastoma Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Chemotherapy Tablets
Targeted Therapy Tablets
6.6. Global Neuroblastoma Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunotherapy Vaccines
Therapeutic Vaccines
6.7. Global Neuroblastoma Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable Drugs
Monoclonal Antibodies
Cell Therapy Products

7. Neuroblastoma Market Regional And Country Analysis

7.1. Global Neuroblastoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neuroblastoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuroblastoma Market

8.1. Asia-Pacific Neuroblastoma Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuroblastoma Market

9.1. China Neuroblastoma Market Overview
9.2. China Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuroblastoma Market

10.1. India Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuroblastoma Market

11.1. Japan Neuroblastoma Market Overview
11.2. Japan Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuroblastoma Market

12.1. Australia Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuroblastoma Market

13.1. Indonesia Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuroblastoma Market

14.1. South Korea Neuroblastoma Market Overview
14.2. South Korea Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuroblastoma Market

15.1. Western Europe Neuroblastoma Market Overview
15.2. Western Europe Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuroblastoma Market

16.1. UK Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuroblastoma Market

17.1. Germany Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuroblastoma Market

18.1. France Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuroblastoma Market

19.1. Italy Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuroblastoma Market

20.1. Spain Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuroblastoma Market

21.1. Eastern Europe Neuroblastoma Market Overview
21.2. Eastern Europe Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuroblastoma Market

22.1. Russia Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuroblastoma Market

23.1. North America Neuroblastoma Market Overview
23.2. North America Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuroblastoma Market

24.1. USA Neuroblastoma Market Overview
24.2. USA Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuroblastoma Market

25.1. Canada Neuroblastoma Market Overview
25.2. Canada Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuroblastoma Market

26.1. South America Neuroblastoma Market Overview
26.2. South America Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuroblastoma Market

27.1. Brazil Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuroblastoma Market

28.1. Middle East Neuroblastoma Market Overview
28.2. Middle East Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuroblastoma Market

29.1. Africa Neuroblastoma Market Overview
29.2. Africa Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuroblastoma Market Competitive Landscape And Company Profiles

30.1. Neuroblastoma Market Competitive Landscape
30.2. Neuroblastoma Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sartorius AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Recordati S.p.A Overview, Products and Services, Strategy and Financial Analysis

31. Neuroblastoma Market Other Major And Innovative Companies

31.1. United Therapeutics Corporation
31.2. BeiGene Ltd.
31.3. MacroGenics Inc.
31.4. Y-mAbs Therapeutics Inc.
31.5. RedHill Biopharma Ltd.
31.6. Clarity Pharmaceuticals Ltd.
31.7. EUSA Pharma (UK) Ltd.
31.8. US WorldMeds LLC
31.9. Healio Inc.
31.10. Ascentage Pharma
31.11. Laboratorio Elea Phoenix S.A
31.12. Curis Inc.
31.13. PersonGen BioTherapeutics (Suzhou) Co. Ltd.
31.14. Essential Pharma S.A
31.15. Cellectar Biosciences Inc.

32. Global Neuroblastoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuroblastoma Market

34. Recent Developments In The Neuroblastoma Market

35. Neuroblastoma Market High Potential Countries, Segments and Strategies

35.1 Neuroblastoma Market In 2029 - Countries Offering Most New Opportunities
35.2 Neuroblastoma Market In 2029 - Segments Offering Most New Opportunities
35.3 Neuroblastoma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer